In clarity, how are CYDY's patents also different. I understand the protein concentrated and, long acting moelcule, and AVV gene therapy are molecule specific but there are others relating to diseases if I am correct.

Also, aside form the liver disease black box warning) do we have an understanding of how much more clinically effective leronlimab is likely to be than than maraviroc in various disease patholigies (obviously MASH would be a no go for maraviroc due to toxcity). We have said several times times that leornlimab is much better than maraviroc because it isnt just about just blocking CCR5, it is how it does it and how much more effective it is at anticancer activity and healthy immunostabilization. The reason for bringing it up is I believe maraviroc is now available in generic.